Fundamentals screen · refreshed after the Sep 28, 2026 close
Net-cash companies: Healthcare
Companies whose cash and investments exceed all debt by at least a quarter of their market value. Net cash is cash plus short-term investments minus debt, from the latest quarterly balance sheet.
| # | Company | Price | Net cash | Mkt cap | Revenue YoY | P/E |
|---|---|---|---|---|---|---|
| 51 | KYTXKyverna TherapeuticsHealthcare | $6.82 | $174.4M | $421.8M | — | — |
| 52 | EDITEditas MedicineHealthcare | $2.51 | $155.9M | $385.5M | +232.3% | — |
| 53 | BCAXBicara TherapeuticsHealthcare | $18.80 | $497.3M | $1.24B | — | — |
| 54 | IPSCCentury TherapeuticsHealthcare | $1.67 | $119.7M | $302.4M | — | — |
| 55 | NGNENeurogeneHealthcare | $28.48 | $225.4M | $569.9M | — | — |
| 56 | SGMTSagimet Biosciences Inc. Series AHealthcare | $9.94 | $240.1M | $617.9M | — | — |
| 57 | CTKBCytek BiosciencesHealthcare | $5.74 | $261.8M | $746.1M | +5.6% | — |
| 58 | CGEMCullinan TherapeuticsHealthcare | $14.95 | $334.5M | $962.1M | — | — |
| 59 | AVRAnteris Technologies GlobalHealthcare | $7.74 | $256.9M | $754.3M | +63.3% | — |
| 60 | CRSPCRISPR Therapeutics AGHealthcare | $54.09 | $1.78B | $5.23B | +1041.4% | — |
| 61 | NKTRNektar TherapeuticsHealthcare | $60.40 | $684.3M | $2.06B | −9.3% | — |
| 62 | ZVRAZevra TherapeuticsHealthcare | $11.30 | $221.6M | $671.0M | +53.3% | 11.6× |
| 63 | STTKShattuck LabsHealthcare | $6.43 | $208.3M | $645.3M | — | — |
| 64 | CBIOCrescent BiopharmaHealthcare | $14.53 | $171.6M | $539.7M | — | — |
| 65 | OCULOcular TherapeutixHealthcare | $7.66 | $525.8M | $1.68B | +0.1% | — |
| 66 | SBCSBC Medical Group Holdings IncorporatedHealthcare | $5.03 | $160.4M | $517.3M | +13.4% | 10.6× |
| 67 | AGIOAgios PharmaceuticalsHealthcare | $33.42 | $617.6M | $2.00B | +259.3% | — |
| 68 | ODTXOdyssey TherapeuticsHealthcare | $21.47 | $310.6M | $1.03B | — | — |
| 69 | VIRVir BiotechnologyHealthcare | $10.51 | $532.7M | $1.78B | +19582.5% | — |
| 70 | PTCTPTC TherapeuticsHealthcare | $65.95 | $1.63B | $5.50B | +101.5% | — |
| 71 | COAGHemab Therapeutics HoldingsHealthcare | $33.12 | $457.5M | $1.55B | — | — |
| 72 | SRZNSurrozenHealthcare | $29.64 | $102.0M | $348.4M | +408.6% | — |
| 73 | CLDXCelldex TherapeuticsHealthcare | $31.49 | $717.6M | $2.47B | −97.0% | — |
| 74 | MOVMovado GroupHealthcare | $33.48 | $211.6M | $747.0M | +4.9% | 18.1× |
| 75 | IMMXImmix BiopharmaHealthcare | $11.47 | $232.1M | $820.6M | — | — |
| 76 | QUREuniQureHealthcare | $39.11 | $760.2M | $2.71B | +11.0% | — |
| 77 | PBLSParabilis MedicinesHealthcare | $32.57 | $1.11B | $4.02B | — | — |
| 78 | ANNXAnnexonHealthcare | $4.01 | $209.2M | $760.2M | — | — |
| 79 | NTLAIntellia TherapeuticsHealthcare | $11.42 | $437.8M | $1.60B | −46.2% | — |
| 80 | RAPPRapport TherapeuticsHealthcare | $33.44 | $436.1M | $1.60B | — | — |
| 81 | CLYMClimb BioHealthcare | $11.74 | $183.1M | $674.3M | — | — |
| 82 | ACADAcadia PharmaceuticalsHealthcare | $20.53 | $956.5M | $3.54B | +16.4% | 9.3× |
| 83 | SGPSpyGlass PharmaHealthcare | $25.98 | $234.2M | $869.0M | — | — |
| 84 | AVLNAvalyn PharmaHealthcare | $28.32 | $337.6M | $1.26B | — | — |
| 85 | VRDNViridian TherapeuticsHealthcare | $20.57 | $625.7M | $2.33B | +278.7% | — |
| 86 | LBRXLB PharmaceuticalsHealthcare | $37.89 | $327.8M | $1.22B | — | — |
| 87 | DSGNDesign TherapeuticsHealthcare | $12.36 | $207.4M | $773.5M | — | — |
| 88 | RXRXRecursion PharmaceuticalsHealthcare | $3.70 | $531.5M | $1.98B | −60.1% | — |
| 89 | RZLTRezolute, Inc. Common Stock (NV)Healthcare | $4.18 | $107.8M | $404.3M | — | — |
| 90 | ELVNEnliven TherapeuticsHealthcare | $46.01 | $895.2M | $3.37B | — | — |
| 91 | IRONDisc MedicineHealthcare | $64.92 | $658.4M | $2.49B | — | — |
| 92 | XENEXenon PharmaceuticalsHealthcare | $36.72 | $930.7M | $3.56B | — | — |
| 93 | SPTXSeaport TherapeuticsHealthcare | $19.64 | $273.3M | $1.05B | — | — |
| 94 | FTHFaeth TherapeuticsHealthcare | $27.77 | $186.4M | $717.6M | — | — |
| 95 | AVBPArriVent BioPharmaHealthcare | $29.30 | $373.1M | $1.44B | — | — |
Method & sources
Computed after each close from Massive / Polygon prices (split-adjusted), SEC filings, FINRA short-interest settlements and FMP earnings dates. Rows are rebuilt every session; a stock appears only when every criterion is met with current data. Full methodology
Informational screen, not a recommendation.